Alnylam Pharmaceuticals, Inc. (ALNY)
Biotechnology · Healthcare · $36.8B
Intrinsic Value (Consensus)
$90.36
Current Price
$278.13
Margin of Safety
-67.5%
67.5% Above Intrinsic Value
Value: $90
Price: $278
Valuation Model Estimates
Current Price: $278.13
DCF (Discounted Cash Flow)
$578.53
Graham Number
$23.67
Earnings Power Value
$57.24
Relative Value (P/E)
$123.48
Dividend Discount Model
Not applicable
—
Consensus Value
$90.36
Model Assumptions
Discount Rate
10.3%
Growth Rate
29.5%
Terminal Growth
2.5%
Risk-Free Rate
4.3%
Discount rate derived from CAPM (risk-free rate + beta × market risk premium). Growth rate based on trailing earnings growth, capped at 20%.
Health Score
B
77
Profitability
25/25
Strength
20/25
Valuation
7/25
Growth
25/25
Financial Health Signals
Strong profitability — ROE of 40% (above 20% is excellent)
Strong earnings growth (30% YoY)
Key Financials
- EPS (TTM)
- $4.18
- EPS (Forward)
- $5.41
- Book Value
- $5.96
- P/E Ratio
- 20.0
- Forward P/E
- 16.7
- PEG Ratio
- —
- ROE
- 39.8%
- Debt/Equity
- 86%
- Revenue Growth
- 65.2%
- Earnings Growth
- 29.5%
- Dividend Yield
- N/A
- Beta
- 0.27
Similar Stocks (Healthcare)
ABEOAbeona Therapeutics ...
$37.06+300%
ABUSArbutus Biopharma Co...
$18.93+300%
ADVBAdvanced Biomed Inc....
$26.66+300%
AGENAgenus Inc.
$20.19+300%
ATRAAtara Biotherapeutic...
$41.43+300%
Data last updated: 2026-06-21
Source: Yahoo Finance